The source of the HLA class I antigens in RBC units causing sensitization is currently unknown. SCD may be at higher risk for transfusion-related alloimmunization. Keywords: sickle cell disease, H-Y, HLA antibody, alloimmunization, transfusion Introduction Blood component transfusions are crucial to the care of patients with sickle cell disease (SCD), severe aplastic anaemia, thalassaemia and other haematological diseases. Alloimmunization to red blood cell (RBC) antigens places these patients at risk for serious haemolytic transfusion reactions and can dangerously restrict their access to life-saving blood. In addition, if these patients undergo haematopoietic stem cell transplantation (HSCT), alloimmunization to histocompatibility antigens from transfusions may complicate transplantation. The capacity of RBC transfusions Pipendoxifene hydrochloride to cause human leucocyte antigen (HLA) alloimmunization (Balasubramaniam, 2012, Karpinski 2004, van de Watering, 2003) and of this alloimmunization to contribute to HSCT rejection has been firmly established (Brand, 2013, Ciurea, 2009, Ciurea, 2011, Cutler, 2011, Ruggeri, 2013, Spellman, 2010, Takanashi, 2010, Yoshihara, 2012). However, less is known about alloimmunization against minor histocompatibility antigens (mHA), self-peptides presented by HLA and targets of the host-versus-graft response in HLA-matched transplants. Canine and murine models have provided evidence of the capacity of transfusion-related mHA alloimmunization to induce HSCT rejection (Desmarets, 2009, Patel, 2009, Patel and Zimring 2013, Storb, 1970, Storb, 1971, Storb, 1979). While some studies suggest pre-transplant transfusions may increase the risk of HLA-identical HSCT rejection in patients with aplastic anaemia due to mHA alloimmunization (Champlin, 1989, Deeg, 1986, Sanders, 1994, Storb, 1983), it remains unclear whether, in current clinical practice, transfusions actually cause significant alloimmune responses to mHA. Clinical investigation into this matter has been hampered by the lack of an assay suitable for assessing mHA alloimmunization. With the recent development of a multiplex antibody assay, it has become feasible to Pipendoxifene hydrochloride clinically study immunity to one group of mHA: H-Y antigens (Wadia, 2011). H-Y antigens are encoded by the Y chromosome and thus expressed uniquely in males. They can elicit both cellular and humoral immune responses (Porcheray, 2011, Zorn, 2004) and have been implicated in the increased HLA-identical HSCT rejection rates observed in female patients who received male grafts (Goulmy, 1982, Spierings, 2003, Stern, 2006). Previously, we have exhibited the association of H-Y antibodies with rejection of renal allografts from male donors by female patients (Tan, 2008), secondary recurrent miscarriage (Nielsen, 2010) and chronic graft-versus-host disease in male recipients of HSC grafts from female donors (Miklos, 2005). In this study, we sought to determine if H-Y alloimmunization occurs after RBC transfusions. Though RBCs do not express H-Y Pipendoxifene hydrochloride antigens (Bradley, 1986, Crichton 1980, Muller, 1980) (or HLA), RBC models contain other potentially immunogenic substances in addition to RBCs, most notably residual leucocytes that remain despite leucoreduction. These leucocytes would be expected to express both HLA and mHA, including H-Y antigens if from a male blood Pipendoxifene hydrochloride donor. We conducted this study of H-Y alloimmunization in children with SCD given the potential clinical importance of such immunization in a patient populace who not only has a frequent need for transfusion therapy, but who also may ultimately undergo HSCT. HSCT is the only cure for this serious disease and there has been constant growth in the use of HSCT for SCD, including the extension of HSCT Rabbit polyclonal to Kinesin1 to adults with the use of non-myeloablative conditioning (Hsieh, 2014). A secondary objective of our study was to more fully assess transfusion-related HLA alloimmunization in SCD patients, a matter of great relevance to current efforts to extend haploidentical HSCT to these patients (Bolanos-Meade, 2012). While it has been exhibited that HLA alloimmunization is usually prevalent among multiply transfused patients with SCD (Ben Salah, 2014, Friedman, 1996, McPherson, 2010), the contribution of transfusion therapy itself has not been defined in this populace in the era of RBC product leucocyte reduction. This study was thus designed to provide a rigorous assessment of Pipendoxifene hydrochloride HLA alloimmunization secondary to leucoreduced RBC transfusions, as well as provide the first clinical assessment of transfusion-mediated mHA alloimmunization. Methods Study Design, Participants and Sample Acquisition We conducted a cross-sectional study of patients age 2 years with SCD SS or S0 at Childrens Healthcare of Atlanta (CHOA) between October 2012 and May 2013..